Arkolith/Insider Trading/CTNM/Form 4

Lorrain Daniel S.

Chief Scientific OfficerContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Feb 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$6K
Net Open-Market Flow
-$6K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 11, 2026Option exercise(M)400$1.01$404156K
Feb 11, 2026Sell(S)400$16.00$6K156K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 11, 2026Option exercise(M)400—$076K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-004122) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML